Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.17p 0.00p 0.00p - - - 0 05:00:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 32.48

Vernalis Share Discussion Threads

Showing 3401 to 3424 of 3850 messages
Chat Pages: Latest  142  141  140  139  138  137  136  135  134  133  132  131  Older
DateSubjectAuthorDiscuss
12/9/2017
20:19
http://www.telegraph.co.uk/news/2017/09/12/nhs-fears-worst-flu-season-history/
romeike
12/9/2017
14:58
exactly, insufficient detail on this important matter given that Suir went into liquidation in May 2016 which is more than a year ago now
bountyhunter
12/9/2017
12:52
- the Company has progressed a new source of supply. Again this is all talking out the side of the mouth stuff. In all likelihood the company has not progressed anything other than negotiating with people who bought the old Suir assets (IQ Pharmatek) for them to continue to supply Moxatag under contract. The continuation of supply is not particularly interesting, what we want to know is what are the terms on which this drug is being supplied and will Vernalis actually make any significant margin on it. We await details but I would anticipate Vernalis is looking at a much reduced margin on this product.
romeike
12/9/2017
10:43
yes encouraging revenue increases but costs need to be reduced and should be some target dates on this bit imho... "We are also working closely with our partner Tris and the FDA to resubmit the NDAs for CCP-07 and CCP-08 as quickly as possible." and this is a bit too vague for my liking, again missing a target date other than sometime in 2018... "The previous manufacturer of Moxatag(R) , Suir, went into liquidation in May 2016. During the year, the Company has progressed a new source of supply and intends to manufacture Moxatag(R) in 2018."
bountyhunter
12/9/2017
07:36
So while revenues are indeed better than expected, mostly down to the research department, the company was less than upfront in its update when ir said costs would be below expected. As it turns out costs are up sharply at over 20mil. At the current rate of burn the company has only a few years before being forced to go back to market.
romeike
11/9/2017
11:47
Don't hold your breath for any new information tomorrow. There is still no FDA warning letters appearing for 2017 regarding Tris. Isn't it about time Vernalis let investors know what the hell is going on?
romeike
10/9/2017
06:24
Results due Tuesday.As important as the performance of Tuzistra will be clarification on the FDA relationship and a supply agreement for Moxatag.Is it too much to hope for?
fhmktg
31/8/2017
23:06
Wow! Mucho buying...... news on the way?
fhmktg
31/8/2017
18:30
With suspenders, you lucky man
ffp
31/8/2017
17:21
Somebody is stocking up!
fhmktg
22/8/2017
12:56
Share price propped up by bottom feeders. Not going to make any significant moves until a new strategy is made clear and we get some positive news. But yes, at least this isn't PFG of subprime vehicle finance fame - chances of recovery looking slim there. More likely it will end in administration.
romeike
22/8/2017
11:05
Like PFG another one of Woodford's. He's reputation surely in tatters now!!
barbar7619
16/8/2017
12:52
is that this year or next ;-)
bountyhunter
16/8/2017
10:50
If the last update is actually stuck to we should perhaps expect confirmation on 12 September that the sales force have begun active promotion of Moxatag®. I remain sceptical though :(
romeike
15/8/2017
12:26
A corporate transaction? Like a buyout? Who would buy Vernalis? Right now it looks like a good research business with a very expensive fledgling commercial pharma unit that looks like it is in danger of failing, burdened with costs for 100 sales staff, an extremely expensive CEO and all propped up by relatively low revenues from a single seasonal product. The companies revenue doesn't even cover the CEO's annual bonus. Is this company being run in the best interest of shareholders? I don't think so.
romeike
15/8/2017
08:59
Need some kind of corporate transaction, let us hope the big shareholders are pushing for this........
chrisdgb
15/8/2017
08:50
Another share price record low. What is Ian Garland and the exec doing about it? We have no idea because they are too busy hiding.
romeike
11/8/2017
06:57
Raised to a BUY at Panmure Gordon with 31p price target...........
chrisdgb
10/8/2017
18:51
hTTp://www.bbc.co.uk/programmes/p05b9q38 President Trump believes he can fight the 'Opioid Epidemic' They pay extra for coloured box! I don't.
bageo
10/8/2017
09:16
The once a day formulation prevents the overdosing on codeine products that so commonly happens with cough/cold treatments, and controls symptoms at a lower dosage meaning a safer profile / less side effects and much lower risk of addiction. These benefits are well established in healthcare and extended release, lower dose drugs will increasingly be the norm. Have you heard of the opoid crisis? While more expensive than multi dose the cost is still generally insignificant. The price the patient actually pays is nothing like the price you suggest above, but that is a matter for the US insurance industry and its uniquely complicated drug pricing structure. Why do Brits pay over £6 for a colourful branded pack of ibuprofen when you can buy exactly the same medication for under 50p a pack. That makes even less sense to me.
romeike
10/8/2017
07:53
Are the Americans stupid enough to overpay for simple products just because they are long acting formulations ? I can understand paying a few dollars more for the convenience but 100's more ? Woodford must have invested because of the other products.
haroldthegreat
10/8/2017
07:31
Do we not think that Woodford could something going here....???? One of his private companies reversed in..??
chrisdgb
09/8/2017
14:01
I know, just teasing;-)
pugg1ey
09/8/2017
13:57
Manufactured by Tris Pharma in New Jersey, USA
romeike
Chat Pages: Latest  142  141  140  139  138  137  136  135  134  133  132  131  Older
Your Recent History
LSE
VER
Vernalis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181216 19:53:10